Tropical parasitic and infectious diseases, such as leishmaniasis, pose enormous global health threats, but are largely neglected in commercial drug discovery programs. However, the Panama International Cooperative Biodiversity Group (ICBG) has been working to identify novel treatments for malaria, Chagas' disease, and leishmaniasis through an investigation of plants and microorganisms from Panama. We have pursued activity-guided isolation from an extract of Lyngbya majuscula that was found to be active against leishmaniasis. A new modified linear peptide from the dragonamide series was isolated, dragonamide E (1), along with two known modified linear peptides, dragonamide A (2) and herbamide B (3). Dragonamides A and E and herbamide B exhibited antileishmanial activity with IC50 values of 6.5, 5.1, and 5.9 microM, respectively. Spectroscopic and stereochemical data for dragonamide E (1) and herbamide B (3; the spectroscopic and stereochemical data for this substance is incomplete in the literature) are presented as well as comparisons of biological activity within the dragonamide compound family. Biosynthetic differences among marine compounds with a terminal free amide are also discussed.
Tropical parasitic and class="Disease">infectious diseases, such as n class="Disease">leishmaniasis, pose enormous global health threats, but are largely neglected in commercial drug discovery programs. However, the Panama International Cooperative Biodiversity Group (ICBG) has been working to identify novel treatments for malaria, Chagas' disease, and leishmaniasis through an investigation of plants and microorganisms from Panama. We have pursued activity-guided isolation from an extract of Lyngbya majuscula that was found to be active against leishmaniasis. A new modified linear peptide from the dragonamideseries was isolated, dragonamide E (1), along with two known modified linear peptides, dragonamide A (2) and herbamide B (3). Dragonamides A and E and herbamide B exhibited antileishmanial activity with IC50 values of 6.5, 5.1, and 5.9 microM, respectively. Spectroscopic and stereochemical data for dragonamide E (1) and herbamide B (3; the spectroscopic and stereochemical data for this substance is incomplete in the literature) are presented as well as comparisons of biological activity within the dragonamide compound family. Biosynthetic differences among marine compounds with a terminal free amide are also discussed.
Authors: Patricia M Flatt; Susan J O'Connell; Kerry L McPhail; Gloria Zeller; Christine L Willis; David H Sherman; William H Gerwick Journal: J Nat Prod Date: 2006-06 Impact factor: 4.050
Authors: Zunxue Chang; Patricia Flatt; William H Gerwick; Viet-Anh Nguyen; Christine L Willis; David H Sherman Journal: Gene Date: 2002-08-21 Impact factor: 3.688
Authors: Kerry L McPhail; Jhonny Correa; Roger G Linington; José Gonzalez; Eduardo Ortega-Barría; Todd L Capson; William H Gerwick Journal: J Nat Prod Date: 2007-04-19 Impact factor: 4.050
Authors: J Nieto; D Veelaert; R Derua; E Waelkens; A Cerstiaens; G Coast; B Devreese; J Van Beeumen; J Calderon; A De Loof; L Schoofs Journal: Biochem Biophys Res Commun Date: 1998-07-20 Impact factor: 3.575
Authors: Christopher M Pavlik; Christina Y B Wong; Sophia Ononye; Dioxelis D Lopez; Niclas Engene; Kerry L McPhail; William H Gerwick; Marcy J Balunas Journal: J Nat Prod Date: 2013-10-28 Impact factor: 4.050
Authors: Shaden A M Khalifa; Eslam S Shedid; Essa M Saied; Amir Reza Jassbi; Fatemeh H Jamebozorgi; Mostafa E Rateb; Ming Du; Mohamed M Abdel-Daim; Guo-Yin Kai; Montaser A M Al-Hammady; Jianbo Xiao; Zhiming Guo; Hesham R El-Seedi Journal: Mar Drugs Date: 2021-04-24 Impact factor: 5.118